Gilead's Truvada cut risk of HIV infection by up to 78% in heterosexuals
This article was originally published in Scrip
Executive Summary
Results of two new studies reported on 13 July have provided more compelling evidence that daily pre-exposure prophylaxis (PrEP) treatment with antiretroviral therapies (ARTs) can prevent the spread of HIV infection – demonstrating for the first time that the drugs significantly reduced the risk of acquiring the AIDS-causing virus in heterosexual men and women, the population hardest hit by the disease.